200,000 shares of Vir Biotechnology, Inc. (NASDAQ:VIR) bought by Affinity Asset Advisors LLC

VaselineSeptember 25, 2024

0 4 minutes read

Affinity Asset Advisors LLC purchased a new stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIR – Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 200,000 shares of the company’s stock, valued at approximately $1,780,000. Affinity Asset Advisors LLC owned approximately 0.15% of Vir Biotechnology as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in VIR. Caxton Associates LP purchased a new position in Vir Biotechnology in the second quarter valued at $531,000. Point72 Asia Singapore Pte. Ltd. increased its holdings in Vir Biotechnology by 491.7% in the 2nd quarter.Point72 Asia Singapore Pte. Ltd. now owns 18,959 shares of the company’s stock valued at $169,000 after buying an additional 15,755 shares during the last quarter. Point72 Hong Kong Ltd raised its position in Vir Biotechnology by 180.6% in the second quarter. Point72 Hong Kong Ltd now owns 19,572 shares of the company’s stock worth $174,000 after buying an additional 12,598 shares during the period. Cubist Systematic Strategies LLC increased its position in Vir Biotechnology by 6,402.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 188,624 shares of the company’s stock worth $1,679,000 after buying an additional 185,723 shares during that period. Finally, Point72 DIFC Ltd lifted its stake in Vir Biotechnology by 199.9% in the second quarter. Point72 DIFC Ltd now owns 26,917 shares of the company’s stock worth $240,000 after buying an additional 17,941 shares during the last quarter. 65.32% of the shares are held by hedge funds and other institutional investors.

Vir Biotechnology trading down 0.8%

Shares of VIR stock opened at $7.54 on Wednesday. Vir Biotechnology, Inc. has a 12-month low of $7.41 and a 12-month high of $13.09. The stock has a fifty day simple moving average of $8.72 and a two hundred day simple moving average of $9.31. The stock has a market cap of $1.03 billion, a price-to-earnings ratio of -1.88 and a beta of 0.46.

Want more great investment ideas?

Vir Biotechnology (NASDAQ:VIR – Get Free Report ) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.13). The business had revenue of $3.08 million during the quarter, compared to analysts’ expectations of $7.53 million. Vir Biotechnology had a negative return on equity of 30.93% and a negative net margin of 612.40%. Vir Biotechnology’s revenue for the quarter was down 19.0% on a year-over-year basis. During the same period in the previous year, the company posted EPS of ($1.45). Research analysts predict that Vir Biotechnology, Inc. will post -3.26 EPS for the current fiscal year.

Insider Trading at Vir Biotechnology

In other Vir Biotechnology news, Director Janet Napolitano sold 12,190 shares of Vir Biotechnology stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $7.80, for a total value of $95,082.00. Following the transaction, the director now owns 11,616 shares in the company, valued at $90,604.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available on the SEC’s website. Corporate insiders own 15.60% of the company’s shares.

The Wall Street analyst weighs in

A number of equities research analysts have recently issued reports on VIR shares. Needham & Company LLC upped their target price on Vir Biotechnology from $15.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, June 5th. Barclays upped their target price on shares of Vir Biotechnology from $27.00 to $28.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $110.00 target price on shares of Vir Biotechnology in a research note on Tuesday, August 20th. Finally, Morgan Stanley raised their price objective on shares of Vir Biotechnology from $12.00 to $15.00 and gave the company an “equal weight” rating in a report on Thursday, June 6th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $36.80.

See the latest stock analysis on VIR

Profile Biotechnology Vir

(Free Report)

Vir Biotechnology, Inc, a commercial immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Provides tobevibart + elebsiran for the treatment of chronic delta hepatitis; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of human respiratory syncytial virus/metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of precancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the brand name Xevudy.